Login to Your Account



No more talk: Novartis balks at Colombia price negotiations for Glivec

By Sergio Held
Staff Writer

Friday, April 22, 2016

HONG KONG – Novartis AG pulled out of negotiations with the government of Colombia to determine a price for the leukemia drug Glivec (imatinib). Discussions had been initiated to prevent the issuance of a mandatory license. (See BioWorld Today, April 22, 2016.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription